Manager TitleAgeSince
Chief Executive Officer 62 2023-01-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 55 2017-07-31
Director TitleAgeSince
Director/Board Member 61 -
Chairman 78 -
Chairman 63 2023-01-16
Change 5-day change 1-year change 3-year change Capi.($)
-4.44%+21.43% - - 6.31M
+0.27%+6.97%+25.86%+15.41% 233B
+1.36%+8.10%+3.33%-14.13% 154B
+1.16%-3.98%-20.44%+30.45% 134B
+2.03%-2.82%-52.56%+0.04% 73B
+0.98%+2.26%-16.22%-12.85% 52.24B
-0.04%-1.98%+9.73%+18.30% 51.75B
+1.73%+7.05%+30.72%+33.47% 44.91B
+1.49%-0.36%+35.91%+51.53% 40.35B
+1.03%+1.53%-0.53%+8.45% 33.8B
Average +0.44%+1.86%+1.76%+14.52% 90.71B
Weighted average by Cap. +0.90%+3.06%+2.97%+11.80%

Financials

2024 2025
Net sales 10.51M 1.11M 951K 890K 814K 1.53M 106M 1.55M 4.1M 53.35M 4.17M 4.08M 176M 16.65M 1.76M 1.51M 1.41M 1.29M 2.42M 168M 2.45M 6.49M 84.49M 6.6M 6.46M 279M
Net income -20.18M -2.13M -1.83M -1.71M -1.56M -2.93M -204M -2.97M -7.87M -102M -8M -7.83M -339M -17.52M -1.85M -1.58M -1.48M -1.36M -2.55M -177M -2.58M -6.83M -88.92M -6.95M -6.8M -294M
Net Debt - -
Logo Phase Holographic Imaging PHI AB
Phase Holographic Imaging PHI AB (PHI) is a Sweden-based company active in the field of medical technology. It develops and markets time-lapse cytometers for clinical applications. The products use holographic microscopy technology, with image sensors capturing light information from objects, and computer processing the information to create visual image. It is also engaged in the development of related software. Its method allows to view and measure living cell over time, without disturbing or destroying it. PHI collaborates with cancer- and stem cell researchers, among others. The Company’s product portfolio includes HoloMonitor M3, a bench-top time-lapse cytometer, and HoloMonitor M4, allowing cell analysis in the cultivation incubator.
Employees
15